tbuckley/cabot-search huggingface dataset:
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Authors: Sally F. Barrington, N. George Mikhaeel, Lale Kostakoglu, Michel Meignan, Martin Hutchings, Stefan P. Müeller, Lawrence H. Schwartz, Emanuele Zucca, Richard I. Fisher, Judith Trotman, Otto S. Hoekstra, Rodney J. Hicks, Michael J. O'Doherty, Roland Hustinx, Alberto Biggi, Bruce D. Cheson
Journal: Journal of Clinical Oncology (2014)

Recent advances in imaging, use of prognostic indices, and molecular profiling techniques have the potential to improve disease characterization and outcomes in lymphoma. International trials are under way to test image-based response–adapted treatment guided by early interim positron emission tomography (PET)–computed tomography (CT). Progress in imaging is influencing trial design and affecting clinical practice. In particular, a five-point scale to grade response using PET-CT, which can be adapted to suit requirements for early- and late-response assessment with good interobserver agreement, is becoming widely used both in practice- and response-adapted trials. A workshop held at the 11th International Conference on Malignant Lymphomas (ICML) in 2011 concluded that revision to current staging and response criteria was timely.An imaging working group composed of representatives from major international cooperative groups was asked to review the literature, share knowledge about research in progress, and identify key areas for research pertaining to imaging and lymphoma.A working paper was circulated for comment and presented at the Fourth International Workshop on PET in Lymphoma in Menton, France, and the 12th ICML in Lugano, Switzerland, to update the International Harmonisation Project guidance regarding PET. Recommendations were made to optimize the use of PET-CT in staging and response assessment of lymphoma, including qualitative and quantitative methods.This article comprises the consensus reached to update guidance on the use of PET-CT for staging and response assessment for [18F]fluorodeoxyglucose-avid lymphomas in clinical practice and late-phase trials.
Dialysate as Food
Authors: Hoey Lan Tjiong, Jacobus W. van den Berg, Josias L. Wattimena, Trinet Rietveld, Laurens J. van Dijk, Adorée M. van der Wiel, Anneke M. van Egmond, Marien W. Fieren, Roel Swart
Journal: Journal of the American Society of Nephrology (2005)

Protein-energy malnutrition as a result of anorexia frequently occurs in dialysis patients. In patients who are on peritoneal dialysis (PD), dialysate that contains amino acids (AA) improves protein anabolism when combined with a sufficient oral intake of calories. It was investigated whether protein anabolism can be obtained with a mixture of AA plus glucose (G) as a source of proteins and calories during nocturnal automated PD (APD). A random-order cross-over study was performed in eight APD patients to compare in two periods of 7 d each AA plus G dialysate obtained by cycler-assisted mixing of one bag of 2.5 L of AA (Nutrineal 1.1%, 27 g of AA) and four bags of 2.5 L of G (Physioneal 1.36 to 3.86%) versus G as control dialysate. Whole-body protein turnover was determined using a primed continuous infusion of L-[1-13C]leucine, and 24-h nitrogen balance studies were performed. During AA plus G dialysis, when compared with control, rates of protein synthesis were 1.20 +/- 0.4 and 1.10 +/- 0.2 micromol/kg per min leucine (mean +/- SD), respectively (NS), and protein breakdown rates were 1.60 +/- 0.5 and 1.72 +/- 0.3 micromol/kg per min (NS). Net protein balance (protein synthesis minus protein breakdown) increased on AA plus G in all patients (mean 0.21 +/- 0.12 micromol leucine/kg per min; P < 0.001). The 24-h nitrogen balance changed by 0.96 +/- 1.21 g/d, from -0.60 +/- 2.38 to 0.35 +/- 3.25 g/d (P = 0.061, NS), improving in six patients. In conclusion, APD with AA plus G dialysate improves protein kinetics. This dialysis procedure may improve the nutritional status in malnourished PD patients.
Response to: ‘On the TIDES study’, by Quittner<i>et al</i>
Authors: Mandy Bryon, A Kevin Webb
Journal: Thorax (2015)

Dear editors

In response to the correspondence by Quittner et al , we have the following comments. It must be stated that we think your The International Depression Epidemiological Study (TIDES) paper1 has merit, and we commend any endeavours to highlight the mental health issues of people with cystic fibrosis (CF) and improvements in psychosocial service provision. The editorial has no intention of minimising the extent of the problem, quite the opposite. Your publication (and further correspondence) reports on two different issues: first, the TIDES study, and second, the recommendations of the International Guidelines Committee on Mental Health (IGCMH) in CF. The second is dependent on the findings of the first. So, the TIDES paper has methodological weaknesses and inconsistencies between the various publications that have devolved from the study.2 ,3 The TIDES authors must be conscientious in the conclusions they draw and the level of clinical significance that is …
Protein-releasing polymeric scaffolds induce fibrochondrocytic differentiation of endogenous cells for knee meniscus regeneration in sheep
Authors: Chang H. Lee, Scott A. Rodeo, Lisa Ann Fortier, Chuanyong Lu, Cevat Erisken, Jeremy J. Mao
Journal: Science Translational Medicine (2014)

Sheep knee meniscus was regenerated by spatiotemporal delivery of two recombinant human proteins in 3D-printed bioresorbable scaffold.
Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines
Authors: Hongli Shan, Yong Zhang, Yanjie Lu, Ying Zhang, Zhenwei Pan, Benzhi Cai, Ning Wang, Xuelian Li, Tieming Feng, Yuan Hong, Baofeng Yang
Journal: Cardiovascular Research (2009)

The present study was designed to decipher molecular mechanisms underlying nicotine's promoting atrial fibrillation (AF) by inducing atrial structural remodelling. The canine model of AF was successfully established by nicotine administration and rapid pacing. The atrial fibroblasts isolated from healthy dogs were treated with nicotine. The role of microRNAs (miRNAs) on the expression and regulation of transforming growth factor-β1 (TGF-β1), TGF-β receptor type II (TGF-βRII), and collagen production was evaluated in vivo and in vitro. Administration of nicotine for 30 days increased AF vulnerability by ∼eight- to 15-fold in dogs. Nicotine stimulated remarkable collagen production and atrial fibrosis both in vitro in cultured canine atrial fibroblasts and in vivo in atrial tissues. Nicotine produced significant upregulation of expression of TGF-β1 and TGF-βRII at the protein level, and a 60–70% decrease in the levels of miRNAs miR-133 and miR-590. This downregulation of miR-133 and miR-590 partly accounts for the upregulation of TGF-β1 and TGF-βRII, because our data established TGF-β1 and TGF-βRII as targets for miR-133 and miR-590 repression. Transfection of miR-133 or miR-590 into cultured atrial fibroblasts decreased TGF-β1 and TGF-βRII levels and collagen content. These effects were abolished by the antisense oligonucleotides against miR-133 or miR-590. The effects of nicotine were prevented by an α7 nicotinic acetylcholine receptor antagonist. We conclude that the profibrotic response to nicotine in canine atrium is critically dependent upon downregulation of miR-133 and miR-590.
Ofloxacin Monotherapy for the Primary Treatment of Microbial Keratitis
Authors: Carlos Pavesio, Nigel Morlet, Bruce Allan, Hosam El Kassaby, Romain DeCock, Jeremy Butcher, Roger Baer, David Broadway, Stephen J. Charles, Graham Duguid, Peter Heyworth, Chris Jenkins, Genevieve Larkin, Ian C. Lloyd, Andrew McNaught, John Dart, Andrew Tullo, Linda Ficker, Darwin Minassian, Melville Matheson, Alan P. Johnson
Journal: Ophthalmology (1997)
Distribution of common acute lymphoblastic leukemia antigen in nonhematopoietic tissues.
Authors: R S Metzgar, M J Borowitz, N H Jones, B L Dowell
Journal: The Journal of Experimental Medicine (1981)

The common acute lymphoblastic leukemia antigen (CALLA), as defined by J-5 murine monoclonal antibodies, was detected on renal tubular and glomerular cells from fetal and adult donors by an indirect immunoperoxidase technique. CALLA could also be detected on epithelial cells of the fetal small intestine and on myoepithelial cells of adult breast but not on myoepithelial cells of the salivary gland. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of immunoprecipitated 125I-labeled membrane antigens from dissociated renal cells demonstrated that the antigen migrated as a 90,000 mol wt antigen rather than the 98,000-100,000 mol wt antigen noted on CALLA-positive tissue culture cell lines. The data suggest that the determinant defined by the J-5 monoclonal antibody is neither a lymphoid cell-specific differentiation antigen nor a leukemia-specific antigen.
Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma
Authors: M Ladetto, F Zallio, S Vallet, I Ricca, A Cuttica, D Caracciolo, P Corradini, M Astolfi, S Sametti, F Volpato, P Bondesan, U Vitolo, M Boccadoro, A Pileri, AM Gianni, C Tarella
Journal: Leukemia (2001)
Lipoxins in asthma: potential therapeutic mediators on bronchial inflammation?
Authors: C. Bonnans, P. Chanez, C. Chavis
Journal: Allergy (2004)

Arachidonic acid metabolism represents an important source of mediators with ambivalent actions. Among these, lipoxins (LXs) are the first agents identified and recognized as anti‐inflammatory endogenous lipid mediators, which are involved in the resolution of inflammation and are present in the airways of asthmatic patients. Lipoxins result mainly from the interaction between 5 and 15‐lipoxygenases (LO) and their levels are modulated by the degree of bronchial inflammation as well as by the long‐term glucocorticoid treatments. In the airways, LX synthesis is higher in mild asthmatics than in severe asthmatics, whereas in vitro chemokine release inhibition by LXs is more effective in cells from severe asthmatics than from mild asthmatics. LipoxinA 4 effects on interleukin (IL)‐8 released by blood mononuclear cells and on calcium influx in epithelial cells are mediated by the specific receptor ALX. Lipoxin generation by lung epithelial cells depends mainly on 15‐LO activity. Mild asthmatics present higher 15‐LOb expression at the epithelium level than severe patients, whereas the LX deficit in severe asthma is associated with an up‐regulation of the 15‐LOa expressions. Therefore, bronchial epithelial cells become a target for therapeutic intervention and LXs represent a potential therapeutic solution for bronchial inflammation resolution in asthma.
Antimalarial ototoxicity: an underdiagnosed complication? A study of spontaneous reports to the French Pharmacovigilance Network: Table 1
Authors: Noemie Jourde-Chiche, Julien Mancini, Nathalie Dagher, Solene Taugourdeau, Guillemette Thomas, Caroline Brunet, Charleric Bornet, Marie-Josephe Pastor, Laurent Chiche
Journal: Annals of the Rheumatic Diseases (2012)

Antimalarial drugs have been prescribed for years to treat several connective-tissue diseases.1 Epidemiological studies now suggest they may play a role in preventing severe complications in systemic lupus erythematosus (SLE).2 Antimalarial drugs are also used off-label for other systemic autoimmune conditions, including sarcoidosis and Sjogren's syndrome. Indeed, antimalarial drugs are inexpensive and have a good safety profile,3 especially hydroxychloroquine,1 and when systematic monitoring of ophthalmological side-effects is initiated.4 However, some cases of audiovestibular toxicity have been reported anecdotally.5,–,7 We conducted this study to evaluate audiovestibular side-effects in patients treated with antimalarial drugs.

All spontaneous reports of audiovestibular adverse events attributed to antimalarial drugs in the French Pharmacovigilance Network database, between January 1986 and …
Multicenter Phase II Study of a 28-Day Regimen of Orally Administered Eniluracil and Fluorouracil in the Treatment of Patients With Anthracycline- and Taxane-Resistant Advanced Breast Cancer
Authors: Edgardo Rivera, Linda Sutton, Bruce Colwell, Mark Graham, Debra Frye, Matt Somerville, Heather S. Conklin, Chip McGuirt, Jeremey Levin, Gabriel N. Hortobagyi
Journal: Journal of Clinical Oncology (2002)

Eniluracil (776C85), a potent inactivator of dihydropyrimidine dehydrogenase, allows fluorouracil (5-FU) to be administered orally on a schedule that simulates continuous-infusion 5-FU. The primary objective of this study was to estimate the objective tumor response rate of orally administered eniluracil and 5-FU in the treatment of anthracycline- and taxane-resistant advanced breast cancer.Patients with anthracycline- and taxane-resistant advanced breast cancer were enrolled onto this open-label, phase II, multicenter study. Patients received orally administered 5-FU 1.0 mg/m(2) with eniluracil given in a 10:1 ratio (eniluracil:5-FU) twice daily for the first 28 days of each 35-day cycle.Eighty-four patients were enrolled. Eight partial responses were observed in 84 patients (10%; 95% confidence interval [CI], 4.2% to 17.9%), and 20 patients (24%) had stable disease. The median duration of partial response was 20.1 weeks (95% CI, 12 to 26.7 weeks). The median duration of progression-free survival and overall survival for all patients was 9.9 weeks and 40.4 weeks, respectively. Most adverse events were grade 1 or 2 in intensity. Diarrhea, nausea, malaise/fatigue, vomiting, and mucositis were the most common treatment-related nonhematologic adverse events. The most frequently occurring grade 3 or 4 treatment-related adverse events were malaise/fatigue and diarrhea, occurring in 17% and 7% of patients, respectively. The incidence of grade 3 or 4 hematologic toxicity was low. Grade 3 or 4 hyperbilirubinemia occurred in 17% of patients.Eniluracil-5-FU has modest antitumor activity and an acceptable safety profile in anthracycline- and taxane-resistant breast cancer. Treatment was convenient, and patient compliance was high.
Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype
Authors: H. Iwamoto, A. Yokoyama, N. Shiota, H. Shoda, Y. Haruta, N. Hattori, N. Kohno
Journal: European Respiratory Journal (2008)

Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma
Authors: A. Gupta, S. Love, A. Schuh, M. Shanyinde, J.M. Larkin, R. Plummer, P.D. Nathan, S. Danson, C.H. Ottensmeier, P. Lorigan, L. Collins, A. Wise, R. Asher, R. Lisle, M.R. Middleton
Journal: Annals of Oncology (2014)
CD4 T cells integrate signals delivered during successive DC encounters in vivo
Authors: Susanna Celli, Zacarias Garcia, Philippe Bousso
Journal: The Journal of Experimental Medicine (2005)

The cellular mode of T cell priming in vivo remains to be characterized fully. We investigated the fate of T cell-dendritic cell (DC) interactions in the late phase of T cell activation in the lymph node. In general, CD4 T cells detach from DCs before undergoing cell division. Using a new approach to track the history of antigen (Ag)-recognition events, we demonstrated that activated/divided T cells reengage different DCs in an Ag-specific manner. Two-photon imaging of intact lymph nodes suggested that T cells could establish prolonged interactions with DCs at multiple stages during the activation process. Importantly, signals that are delivered during subsequent DC contacts are integrated by the T cell and promote sustained IL-2Ralpha expression and IFN-gamma production. Thus, repeated encounters with Ag-bearing DCs can occur in vivo and modulate CD4 T cell differentiation programs.
Chemoprevention of Head and Neck Cancer by Simultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways: Preclinical and Clinical Studies
Authors: Dong M. Shin, Hongzheng Zhang, Nabil F. Saba, Amy Y. Chen, Sreenivas Nannapaneni, A.R.M. Ruhul Amin, Susan Müller, Melinda Lewis, Gabriel Sica, Scott Kono, Johann C. Brandes, William J. Grist, Rachel Moreno-Williams, Jonathan J. Beitler, Sufi M. Thomas, Zhengjia Chen, Hyung Ju C. Shin, Jennifer R. Grandis, Fadlo R. Khuri, Zhuo Georgia Chen
Journal: Clinical Cancer Research (2013)

We investigated the efficacy and underlying molecular mechanism of a novel chemopreventive strategy combining EGF receptor (EGFR) tyrosine kinase inhibitor (TKI) with cyclooxygenase-2 inhibitor (COX-2I).We examined the inhibition of tumor cell growth by combined EGFR-TKI (erlotinib) and COX-2I (celecoxib) treatment using head and neck cancer cell lines and a preventive xenograft model. We studied the antiangiogenic activity of these agents and examined the affected signaling pathways by immunoblotting analysis in tumor cell lysates and immunohistochemistry (IHC) and enzyme immunoassay (EIA) analyses on the mouse xenograft tissues and blood, respectively. Biomarkers in these signaling pathways were studied by IHC, EIA, and an antibody array analysis in samples collected from participants in a phase I chemoprevention trial of erlotinib and celecoxib.The combined treatment inhibited head and neck cancer cell growth significantly more potently than either single agent alone in cell line and xenograft models, and resulted in greater inhibition of cell-cycle progression at G1 phase than either single drug. The combined treatment modulated the EGFR and mTOR signaling pathways. A phase I chemoprevention trial of combined erlotinib and celecoxib revealed an overall pathologic response rate of 71% at time of data analysis. Analysis of tissue samples from participants consistently showed downregulation of EGFR, pERK, and pS6 levels after treatment, which correlated with clinical response.Treatment with erlotinib combined with celecoxib offers an effective chemopreventive approach through inhibition of EGFR and mTOR pathways, which may serve as potential biomarkers to monitor the intervention of this combination in the clinic. Clin Cancer Res; 19(5); 1244-56. ©2013 AACR.
Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.
Authors: Q J Sattentau, J P Moore
Journal: The Journal of Experimental Medicine (1995)

The major target of the neutralizing antibody response to infection by the human immunodeficiency virus type 1 (HIV-1) is the outer envelope glycoprotein, gp120. The spectrum of HIV-1 neutralization specificity is currently represented by monoclonal antibodies (mAbs) that can be divided broadly into five groups. We have studied the binding of these mAbs to functional oligomeric and soluble monomeric gp120 derived from the molecular clone of a cell line-adapted isolate of HIV-1, and compared these binding properties with virus neutralization. Binding of all mAbs except those reactive with the V3 loop was much weaker to oligomeric than to monomeric gp120. This reduction in binding to oligomeric gp120 was determined mostly by a slower relative rate of association, although the dissociation rate also had some influence on relative variation in mAb affinity. Virus neutralization correlated broadly with mAb binding to the oligomeric rather than to the monomeric form of gp120, and neutralization potency was related to the estimated association rate. Thus, with the exception of the hypervariable V3 loop, regions of HIV-1 gp120 with the potential to induce a neutralization response are likely to be poorly presented for antibody recognition on the surface of cell line-adapted virions.
Participation and Outcome in a Residential Treatment and Work Therapy Program for Addictive Disorders: The Effects of Race
Authors: Robert Rosenheck, Catherine Leda Seibyl
Journal: American Journal of Psychiatry (1998)

OBJECTIVE: The authors examined differences in program participation and outcome between black and white veterans with addictive disorders who participated in an intensive Department of Veterans Affairs (VA) residential work therapy program. METHOD: Data on 962 veterans treated in the VA Compensated Work Therapy/Transitional Residence Program were gathered. Multivariate analyses were used to compare black and white veterans on admission characteristics, program participation, and 3-month outcome. RESULTS: The black subjects were younger than the white veterans and had more severe drug abuse problems, less severe alcohol and psychiatric problems, and more extensive social support networks. There were no differences between groups in 11 of 13 measures of program participation, although the blacks felt more positively about the therapeutic milieu and worked more hours per month in the work therapy program than the whites. The black veterans also showed more improvement in alcohol use and housing. The proportion of black participants at the site level had no impact on measures of program participation or outcome among black participants with one exception: blacks were more likely to achieve sobriety at 3 months when treated in programs with higher proportions of black participants. CONCLUSIONS: Detailed data on program participation and outcome in a large study group showed no evidence of less program participation or worse outcome among black patients. (Am J Psychiatry 1998; 155:1029–1034)
Phthalocyanine-Aggregated Polymeric Nanoparticles as Tumor-Homing Near-Infrared Absorbers for Photothermal Therapy of Cancer
Authors: Chang-Keun Lim, Jiyoung Shin, Yong-Deok Lee, Jungahn Kim, Keun Sang Oh, Soon Hong Yuk, Seo Young Jeong, Ick Chan Kwon, Sehoon Kim
Journal: Theranostics (2012)

Phthalocyanine-aggregated Pluronic nanoparticles were constructed as a novel type of near-infrared (NIR) absorber for photothermal therapy. Tiny nanoparticles (~ 60 nm, FPc NPs) were prepared by aqueous dispersion of phthalocyanine-aggregated self-assembled nanodomains that were phase-separated from the melt mixture with Pluronic. Under NIR laser irradiation, FPc NPs manifested robust heat generation capability, superior to an individual cyanine dye and cyanine-aggregated nanoparticles. Micro- and macroscopic imaging experiments showed that FPc NPs are capable of internalization into live cancer cells as well as tumor accumulation when intravenously administered into living mice. It is shown here that continuous NIR irradiation of the tumor-targeted FPc NPs can cause phototherapeutic effects in vitro and in vivo through excessive local heating, demonstrating potential of phthalocyanine-aggregated nanoparticles as an all-organic NIR nanoabsorber for hyperthermia.
Reply to Y. Nishida et al
Authors: Sébastien Salas, Armelle Dufresne, Binh Bui, Jean-Yves Blay, Philippe Terrier, Dominique Ranchere-Vince, Sylvie Bonvalot, Eberhard Stoeckle, Louis Guillou, Axel Le Cesne, Odile Oberlin, Véronique Brouste, Jean-Michel Coindre
Journal: Journal of Clinical Oncology (2012)

Our work 1 that was recently published in Journal of Clinical Oncology simply confirmed the prognostic heterogeneity of sporadic desmoid tumors.In this cohort, we were able to distinguish distinct groups with particular forms of evolution.Indeed, as stated in the discussion section, the retrospective nature of this study cannot determine the method of treatment according to risk.However, the findings should help in future prospective studies that take these different prognostic groups into account to clarify the role of surgery (whether its impact on evolution-free duration is greater in low-risk patients or vice versa), the indications for a wait-and-see policy (whether it is more relevant in low-risk patients or vice versa), and the effects of medical treatment before any locoregional treatment is given.With respect to the correspondence by Nishida et al, 2 it seems hazardous to compare our results with those of other studies that have evaluated the response to different treatments, given that our study is not a prospective study that was aimed at determining the value of one therapeutic strategy compared with another.